In 2011and 2012, meet us at the following events

• Pharma CI Conference and Exhibition, Parsippany, New Jersey from September 13-14, 2011
• Competitive Intelligence in Pharma 2012
• PMRG Annual National Convention, Orlando, FL, Date: March 25 - 27, 2012
• PBIRG AGM, Hyatt Regency, Chicago IL, Date: May 20-23, 2012
• EphMRA, Paris,  Date: June 19-21, 2012

Please attend the following workshops and round table discussions at Pharma CI Conference in Parsippany

• Using CI to Prepare for Generic or Biosimilar Entry on 12th Sep at 1:00-3:25
  • Review of generics and biosimilar landscapes in key global markets
  • Case study presentation
  • Interactive session – Success and failures in preparing for generic or biosimilar entry; development of key intelligence topics
• Collecting Generic CI from India and China at Pharma CI Conference on 13th September 2011 at 1:30-2:30

Announcing our new FREE quarterly webinar series, designed to help market access, pricing, reimbursement, market research, competitive intelligence and business analytics professionals learn new techniques and keep their skills up-to-date.

Complimentary orphan drug market access, pricing, and reimbursement webinar hosted by Lifescience Dynamics Limited.

Orphan drugs are no longer a fringe interest. The world's top three companies are heavily involved, and are behind approvals of 40% orphan drugs in the USA. Throughout the 2000s, orphan drugs accounted for 22% of all NMEs that were FDA approved. PhRMA has recently reported that its member companies have a record 460 drugs in late-stage development for rare diseases.

• Join us in this Free Webinar Wednesday, 20th July - Orphan Drugs in Europe: Are payers still paying premium prices?
  • 10:00am to 10:30am EST
    https://www1.gotomeeting.com/register/557347041
    
  • 10:00am to 10:30 am PDT
    https://www1.gotomeeting.com/register/562238393
    

• Orphan Drugs in Europe: Are payers still paying premium prices?
  • what is the in-market situation with the 60 orphan drugs approved by the end of 2010?
  • vital role of funding
  • what payers won't buy
  • how and where HTA limits access
  • successful company strategies
  • Q&A

The speaker will be Don Macarthur.

Donald Macarthur is Sr. Advisor for Market Access, pricing and reimbursement across Europe and parts of Asia. He publishes extensively and consultancy projects and/or reports covered include:

• Pricing and reimbursement worldwide
• Drug cost containment policy worldwide
• Orphan drugs, from the designation step to market access
• Wholesale and retail distribution, mail order, homecare/specialty pharmacy, cold chain
• Hospital access for medicines in Europe and their funding
• European parallel trade, us (re-)importation
• Generics
• Rx-to-OTC switching
• pricing/reimbursement/funding/market access/distribution in Japan and South Korea.

Don has written 70 major reports and has also founded, edited and published for four years the world’s first periodical on drug pricing and reimbursement, Pharma Pricing Review.

Formerly Secretary General of the European Association of Euro-Pharmaceutical Companies, consultancy clients have included the European Federation of Pharmaceutical Industries and Associations - he was the very first consultant ever used by EFPIA - PhRMA, the European grouping of national full-line pharmaceutical wholesaling associations (GIRP), the UK’s Office of Fair Trading, other government agencies, and many major multinational biopharmaceutical manufacturers, legal and financial firms.

Numerous presentations have been given at international conferences. He has testified as an expert witness at the International Court of Arbitration, and before a US Senate Committee hearing and at the HHS Secretary’s task force hearing on prescription drug importation. His articles have appeared in many English language pharmaceutical business and trade journals, with some translated into Japanese, German, Swedish and Turkish.

Mr Macarthur holds a Bachelor’s degree in Pharmacy from the University of London, and his early career involved community and hospital pharmacy practice, 16 years in development, regulatory affairs and medical department functions in the pharmaceutical industry in the UK (Fisons, 1969-72; Parke-Davis, 1972-75; Roche, 1976-78; Serono, 1978-82; Lundbeck 1982-84), one year in Japan, and four years with PJB Publications (publishers of Scrip).